Cytochrome P450-based cancer gene therapy: recent advances and future prospects.

Cytochrome P450-based cancer gene therapy is a novel prodrug activation strategy for cancer treatment that has substantial potential for improving the safety and efficacy of cancer chemotherapeutics. The primary goal of this strategy is to selectively increase tumor cell exposure to cytotoxic drug metabolites generated locally by a prodrug-activating P450 enzyme. This strategy has been exemplified for the alkylating agents cyclophosphamide and ifosfamide, which are bioactivated by select P450 enzymes whose expression is generally high in liver and deficient in tumor cells. Transduction of tumors with a prodrug-activating P450 gene, followed by prodrug treatment, greatly increases intratumoral formation of activated drug metabolites. This leads to more efficient killing of the transduced tumor cells without a significant increase in host toxicity. P450 gene therapy is accompanied by substantial bystander cytotoxicity which greatly enhances the therapeutic effect by extending it to nearby tumor cells not transduced with the therapeutic P450 gene. Although endogenous P450 reductase is not expected to be a limiting factor in prodrug activation in tumor cells that express moderate levels of an exogenous P450 gene, P450 reductase transduction has recently been found to substantially enhance intratumoral prodrug activation and its associated therapeutic effects. Using this gene combination, an overall 50- to 100-fold increase in tumor cell kill in vivo over that provided by hepatic drug activation alone has been observed. Striking improvements in therapeutic effects can thus be achieved using an established anticancer drug in an intratumoral prodrug activation strategy based on the combination of a cytochrome P450 gene with the gene encoding NADPH-P450 reductase. This strategy is readily extendable to several other widely used P450-activated cancer chemotherapeutic prodrugs, as well as to prodrugs that undergo P450 reductase-dependent bioreductive activation and which may exhibit synergy when combined with P450-activated prodrugs in a P450/P450 reductase-based cancer gene therapeutic regimen.

[1]  M. Grever,et al.  Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9. , 1996, Journal of the National Cancer Institute.

[2]  C. Kasper,et al.  NADPH-cytochrome P-450 oxidoreductase gene organization correlates with structural domains of the protein. , 1990, Biochemistry.

[3]  O. Elroy-Stein,et al.  Retroviral vectors containing putative internal ribosome entry sites: development of a polycistronic gene transfer system and applications to human gene therapy. , 1992, Nucleic acids research.

[4]  C. W. Fisher,et al.  Human cytochrome P450 3A4: enzymatic properties of a purified recombinant fusion protein containing NADPH-P450 reductase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Goldstein,et al.  Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation. , 1997, Pharmacogenetics.

[6]  D. Klatzmann,et al.  Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[7]  D. Waxman,et al.  Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: development of a combined chemotherapy/cancer gene therapy strategy. , 1995, Cancer research.

[8]  D. Kirn,et al.  ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents , 1997, Nature Medicine.

[9]  D. Waxman,et al.  Retroviral transfer of human cytochrome P450 genes for oxazaphosphorine-based cancer gene therapy. , 1998, Cancer research.

[10]  D. Waxman,et al.  Interaction of anticancer drugs with hepatic monooxygenase enzymes. , 1989, Drug metabolism reviews.

[11]  W. Denny,et al.  Mustard prodrugs for activation by Escherichia coli nitroreductase in gene-directed enzyme prodrug therapy. , 1997, Journal of medicinal chemistry.

[12]  J. Whelan,et al.  Progress in transcriptionally targeted and regulatable vectors for genetic therapy. , 1997, Human gene therapy.

[13]  D. Curiel,et al.  Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector , 1997, Nature Biotechnology.

[14]  C. Richards,et al.  In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. , 1993, Cancer research.

[15]  D. Waxman,et al.  Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene. , 1996, Cancer research.

[16]  Adrian L. Harris,et al.  Targeting gene expression to hypoxic tumor cells , 1997, Nature Medicine.

[17]  P. Wen,et al.  Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P450 2B1 gene together with cyclophosphamide. , 1996, Gene therapy.

[18]  Moolten Fl.  Drug sensitivity ("suicide") genes for selective cancer chemotherapy. , 1994 .

[19]  Connors Ta.  The choice of prodrugs for gene directed enzyme prodrug therapy of cancer. , 1995 .

[20]  P. Robbins,et al.  Viral vectors for gene therapy. , 1998, Trends in biotechnology.

[21]  A. Rosowsky,et al.  Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  C. Pratt,et al.  DECHLOROETHYLATION OF IFOSFAMIDE AND NEUROTOXICITY , 1986, The Lancet.

[23]  T. Porter,et al.  An unusual yet strongly conserved flavoprotein reductase in bacteria and mammals. , 1991, Trends in biochemical sciences.

[24]  W. Backes,et al.  Substrate-dependent competition of different P450 isozymes for limiting NADPH-cytochrome P450 reductase. , 1995, Biochemistry.

[25]  G. F. Weber,et al.  Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. , 1993, Cancer research.

[26]  C. Kasper,et al.  NADPH cytochrome P-450 oxidoreductase gene: identification and characterization of the promoter region. , 1994, Archives of biochemistry and biophysics.

[27]  A. Y. Lu,et al.  Studies on the rate-limiting enzyme component in the microsomal monooxygenase system. Incorporation of purified NADPH-cytochrome c reductase and cytochrome P-450 into rat liver microsomes. , 1978, The Journal of biological chemistry.

[28]  B. O’Malley,et al.  Combination gene therapy for oral cancer in a murine model. , 1996, Cancer research.

[29]  D. Kerr,et al.  Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. , 1997, Cancer gene therapy.

[30]  D. Waxman,et al.  Oxidative metabolism of cyclophosphamide: identification of the hepatic monooxygenase catalysts of drug activation. , 1989, Cancer research.

[31]  F. Moolten,et al.  Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. , 1990, Journal of the National Cancer Institute.

[32]  R. Blaese,et al.  Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Waxman,et al.  Thyroid hormone stimulation of NADPH P450 reductase expression in liver and extrahepatic tissues. Regulation by multiple mechanisms. , 1992, The Journal of biological chemistry.

[34]  J. Roth,et al.  Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.

[35]  A. Giaccia,et al.  The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.

[36]  A. Harris,et al.  Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233). , 1995, British Journal of Cancer.

[37]  F. Grosveld,et al.  The expression of bacterial nitroreductase in transgenic mice results in specific cell killing by the prodrug CB1954 , 1997, Gene Therapy.

[38]  D. Waxman,et al.  Potentiation of cytochrome P450/cyclophosphamide-based cancer gene therapy by coexpression of the P450 reductase gene. , 1997, Cancer research.

[39]  M. J. Coon,et al.  Separate roles for FMN and FAD in catalysis by liver microsomal NADPH-cytochrome P-450 reductase. , 1981, The Journal of biological chemistry.

[40]  R. Blaese,et al.  Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5-fluorocytosine and induce protective immunity to wild type tumor. , 1994, Cancer research.

[41]  J. Pawelek,et al.  Tumor-targeted Salmonella as a novel anticancer vector. , 1997, Cancer research.

[42]  P. Ratcliffe,et al.  Hypoxia response elements. , 1997, Oncology research.

[43]  M. Shet,et al.  Construction of plasmids and expression in Escherichia coli of enzymatically active fusion proteins containing the heme-domain of a P450 linked to NADPH-P450 reductase. , 1996, Methods in enzymology.

[44]  D. Waxman,et al.  Regulation of rat hepatic cytochrome P-450: age-dependent expression, hormonal imprinting, and xenobiotic inducibility of sex-specific isoenzymes. , 1985, Biochemistry.

[45]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[46]  X. Breakefield,et al.  Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450 2B1 gene. , 1994, Human gene therapy.

[47]  D. Curiel,et al.  Gene therapy strategies for novel cancer therapeutics. , 1996, Current opinion in oncology.

[48]  N. Sládek.  Metabolism of oxazaphosphorines. , 1988, Pharmacology & therapeutics.

[49]  G. Rosner,et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  T. Wagner,et al.  Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene. , 1998, Human gene therapy.

[51]  G. F. Weber,et al.  Activation of the anti-cancer drug ifosphamide by rat liver microsomal P450 enzymes. , 1993, Biochemical pharmacology.

[52]  A. Hodgson,et al.  NADPH Cytochrome P450 Reductase and Its Structural and Functional Domains , 1995 .

[53]  G. Harsh,et al.  Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. , 1996, Cancer gene therapy.

[54]  D. Waxman,et al.  Hypophysectomy differentially alters P-450 protein levels and enzyme activities in rat liver: pituitary control of hepatic NADPH cytochrome P-450 reductase. , 1989, Molecular pharmacology.

[55]  C. Kasper,et al.  Sequential translocation of two phenobarbital-induced polysomal messenger ribonucleic acids from the nuclear envelope to the endoplasmic reticulum. , 1981, Biochemistry.

[56]  L. Zitvogel,et al.  Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. , 1995, Journal of immunology.

[57]  A. Marrogi,et al.  In situ use of suicide genes for cancer therapy. , 1996, Seminars in oncology.

[58]  A. Kinsella,et al.  The role of the bystander effect in suicide gene therapy. , 1997, European journal of cancer.

[59]  C. Springer,et al.  Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. , 1996, Cancer research.

[60]  I. Stratford,et al.  Targeting gene therapy to cancer: a review. , 1997, Oncology research.